SLC5A2 and type 2 diabetes mellitus: First, the consistency of the effect on kidney outcomesregardless of T2D status or baseline A1C demonstrates that the kidney benefitsare independent of glycemic effects, which is important given that glycemiceffects of SGLT2 inhibitors are reduced at lower levels of eGFR.